Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07011550
Phase
PHASE2
Status
Suspended

Conditions

  • Bevacizumab
  • Microsatellite-stable Colorectal Cancer
  • Nivolumab
  • Standard of Care

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Given by IV
  • Bevacizumab — DRUG
    Given by IV
  • BMS-986340 — DRUG
    Given by IV
  • Trifluridine + Tipiracil — DRUG
    Given by PO

Study Details

To learn if the drug combination of BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab can help to control advanced or metastatic MSS-CRC.

Key Dates

Start date
Aug 15, 2025
Status verified
Mar 2026
Primary completion
Jul 1, 2028
Completion
Jul 1, 2030

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SLI/Exp
    SLI/Exp: Treatment with BMS-986340 + Nivolumab + Trifluridine/tipiracil + Bevacizumab Q4W

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies